Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Science Press Releases.
Press releases published on May 12, 2025

Iron-based nanoparticles in agriculture: promise, peril, or paradox?
GA, UNITED STATES, May 12, 2025 /EINPresswire.com/ -- A sweeping new analysis unpacks the complex role of iron-based nanoparticles (Fe-NPs) in agriculture, revealing a delicate balance between benefit and risk. Synthesizing findings from 57 peer-reviewed …

Tiny titans at high elevations: how soil microbes sustain forest resilience
GA, UNITED STATES, May 12, 2025 /EINPresswire.com/ -- High-altitude forest soils host microscopic communities with outsized influence on ecosystem stability. A recent study unveiled how microbial sub-communities—generalists, intermediates, and …

CMTA-INC Alliance Announces 2025 Inherited Neuropathy Fellowship Recipient
Orthopedic Surgeon to Focus on Improving Outcomes for People with CMT GLENOLDEN, PA, UNITED STATES, May 12, 2025 /EINPresswire.com/ -- The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) …

ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ
PRINCETON, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright …

The EDR Test That Matters - AV-Comparatives to publish the first truly stealth-based EDR test
AV-Comparatives to publish the first truly stealth-based EDR test at the end of May, exposing how today’s security tools fare against APT cyberattacks. INNSBRUCK, TYROL, AUSTRIA, May 12, 2025 /EINPresswire.com/ -- AV-Comparatives, the world-renowned …

Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering
Hopewell, New Jersey, May 12, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally …

AV-Comparatives Publishes New Consumer Cybersecurity Antivirus Test Results – May 2025
Latest Evaluations Reveal Which Cybersecurity and Antivirus Programs Truly Protect – Without Slowing You Down INNSBRUCK, TYROL, AUSTRIA, May 12, 2025 /EINPresswire.com/ -- In a time when cyberattacks are on the rise and personal data is more valuable …

Constellation Software Inc. Announces Results for the First Quarter Ended March 31, 2025 and Declares Quarterly Dividend
TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) (“Constellation” or the “Company”) today announced its financial results for the first quarter ended March 31, 2025 and declared a $1.00 per share dividend payable on July 11, …

Microvast Reports First Quarter 2025 Financial Results
Record company Q1 revenue, increased 43.2% year over year to $116.5 million Gross margin increased from 21.2% to 36.9%, a 15.7 percentage point improvement year over year STAFFORD, Texas, May 12, 2025 (GLOBE NEWSWIRE) -- Microvast Holdings, Inc. (NASDAQ: …

3D Systems Reports First Quarter 2025 Financial Results
ROCK HILL, S.C., May 12, 2025 (GLOBE NEWSWIRE) -- 3D Systems Corporation (NYSE:DDD) announced today its financial results for the first quarter ended March 31, 2025. Revenue of $95 million as growth in new hardware systems and related services was offset …

AirJoule Technologies Announces First Quarter 2025 Results
RONAN, Mont., May 12, 2025 (GLOBE NEWSWIRE) -- AirJoule Technologies Corporation (NASDAQ: AIRJ) (“AirJoule Technologies” or the “Company”), the developer of the transformational AirJoule® system for separating pure water from air, today announced its first …

New 4-Year Data Shows Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism
COPENHAGEN, Denmark, May 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 214 of its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) continued to provide …

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, May 12, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context …

BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD‑1/L1 therapy SEED’s first‑in‑class RBM39 degrader, reported at AACR 2025 for its total tumor regression data in …

Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights
FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Announced positive topline results from Phase 1 study of TNX- …

Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
MORRISTOWN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and …

Satellogic Secures Multi-Million Dollar Agreement with Asia Pacific Customer
DAVIDSON, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Satellogic Inc. (NASDAQ: SATL), a leader in high-resolution Earth observation data, announced today it has entered into a multi-million dollar agreement with an Asia Pacific customer. The agreement provides …

Cellectis Reports Financial Results for the First Quarter 2025
Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025 Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma (r/r NHL) ongoing with readout expected in late 2025 …

Editas Medicine Announces First Quarter 2025 Results and Business Updates
Company to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) at ASGCT this week Company will also share in vivo …

Life360 Reports Record Q1 2025 Results
Monthly Active Users Reached Approximately 83.7 million Record Q1 Global Net Additions to Paying Circles of 137 thousand - Reaching 2.4 million Total Total Quarterly Revenue Grew 32% Year-Over-Year to $103.6 million Annualized Monthly Revenue increased 38% …